Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sandostatin LAR Depot in Obese Patients with Primary Insulin Hypersecretion
NCT00094146Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2002
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of octreotide in obesity (4 arms), sponsored by Novartis. Primary endpoint: Percent Change from Baseline in Body Weight at 6 Months. Started Jan 2002; status: completed.
02
Drugs
octreotide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00094146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094146.